NAD+ and Brain Aging: The Choroid Plexus Control Switch

Scientists have identified a metabolic gatekeeper that drives cognitive decline. By blocking the enzyme CD38, researchers successfully reversed memory loss in aged mice, highlighting a direct functional link between NAD+ and brain aging. The intervention did not merely stop degeneration; it actively restored the chemical environment necessary for learning.

The link between NAD+ and brain aging

Cognitive decline is often treated as a biological mystery. It is not. It is a metabolic failure. This study identifies the choroid plexus—the structure responsible for producing cerebrospinal fluid (CSF)—as the primary site of this failure. As organisms age, the enzyme CD38 accumulates primarily in the pericytes of this region. CD38 is aggressive. It consumes Nicotinamide Adenine Dinucleotide (NAD+), a coenzyme essential for cellular energy.

The consequences are severe. NAD+ depletion triggers mitochondrial dysfunction. Cells enter senescence. The choroid plexus becomes inflamed and fails to regulate the fluid's composition effectively. The brain starves of neurotrophic support. The study measured a direct correlation: high CD38 levels correspond to low NAD+ and high inflammatory markers in the CSF.

Pharmacological Intervention

The research team deployed a novel compound: NTX-748. This is a potent CD38 inhibitor designed to penetrate the blood-brain barrier. When administered to aged mice, the drug effectively suppressed CD38 activity. The results were robust. CD38 activity dropped; NAD+ levels surged. This is not just about chemical balance. It is about functional restoration. The treatment suppressed senescence markers in the choroid plexus and reversed the transcriptional signatures of ageing in the hippocampus.

Mechanism: The Choroid Plexus-Hippocampus Axis

The damage begins in the filtration system but manifests in the memory centre. The hippocampus relies on the CSF for nutrients and signalling molecules. When CD38 is active, the CSF becomes toxic. Inhibiting CD38 cleans the fluid. The proteomic profile shifts. Inflammation subsides. Neurotrophic factors rise.

This rejuvenated fluid bathes the hippocampus. Consequently, synaptic plasticity—the ability of neurons to form new connections—improves. The study measured a restoration of long-term potentiation, the cellular basis for learning. The mice did not just look biologically younger; they performed better in complex cognitive tasks.

Implications for Therapy

The pharmaceutical industry has spent billions attacking amyloid plaques with limited success. This data suggests a different route. It targets upstream metabolism rather than downstream symptoms. The study demonstrates that cognitive resilience depends heavily on the health of the brain's periphery. By maintaining NAD+ levels through CD38 inhibition, it may be possible to delay the onset of senescence. While human biology is more complex than a mouse model, the metabolic pathways are conserved. This offers a pragmatic target for future drug development focused on extending healthspan.